ArticleOncotarget2016
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery.Current obesity reports · 2026Review
- Temporal Dissociation of Impaired Glucose Tolerance, Adipose Lipid Remodeling and Endothelial Dysfunction in Aorta After HFD Withdrawal.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Heart matters: How glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning.Diabetes, obesity & metabolism · 2026Review
- Molecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity.Biomedicines · 2025Review
- Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.Toxicology reports · 2025Review
- Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.F1000Research · 2025Review
- Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.Nutrients · 2024Review
- Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies.Biomedicines · 2024Review
- Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.Frontiers in nutrition · 2024Review
- Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?Journal of endocrinological investigation · 2023Review
- GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.Frontiers in endocrinology · 2023Review
- Approach to Patients with Obesity and Other Cardiovascular Risk Factors in Primary Care Using the Delphi Methodology.Journal of clinical medicine · 2022Article
- Liraglutide suppresses obesity and promotes browning of white fat via miR-27bThe Journal of international medical research · 2021Article
- SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence.Journal of diabetes research · 2021Review
- Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.Frontiers in endocrinology · 2021 · on this mapArticle
- GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions.Frontiers in cell and developmental biology · 2021Article
- Induction of Adipose Tissue Browning as a Strategy to Combat Obesity.International journal of molecular sciences · 2020Review
- An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.Iranian journal of basic medical sciences · 2020Review
- Do Bariatric Surgeries Enhance Brown/Beige Adipose Tissue Thermogenesis?Frontiers in endocrinology · 2020Review
- Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strategies for driving white adipose tissue (WAT) to acquire brown-like characteristics are a promising approach to reduce obesity. Liraglutide has been reported to active brown adipose tissue (BAT) thermogenesis and WAT browning by rapid intracerebroventricular injection in mice. In this study, we investigated the effects and possible mechanisms of liraglutide on WAT browning by chronic treatment. Here, we show that liraglutide significantly decreases body weight of mice and reduces the size of white adipocytes. By quantity polymerase chain reaction, immunoblotting analysis, cell immunofluorescence or immunocytochemical staining, we found liraglutide induced WAT browning because it up-regulated lipolytic activity, BAT, as well as mitochondrial marker genes in inguinal and peripheral renal WAT. We also confirmed liraglutide induced browning of 3T3-L1 because it enhanced expression of BAT and mitochondrial specific genes. In further, we observed that, soluble guanylyl cyclase (sGC) and protein kinase G I (PKGI) were up-regulated by liraglutide in vivo and in vitro; stimulation of sGC elevated expression of BAT markers and PKGI, which suggested that liraglutide induced WAT browning via sGC-dependent pathway. Taken together, this study expands our knowledge on the mechanism of liraglutide inducing WAT browning, and provides a theoretical support for clinical usage of liraglutide on obesity treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.